Medtronic PLC $MDT Shares Sold by Schulhoff & Co. Inc.

Schulhoff & Co. Inc. cut its holdings in Medtronic PLC (NYSE:MDT) by 4.6% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 12,372 shares of the medical technology company’s stock after selling 600 shares during the period. Schulhoff & Co. Inc.’s holdings in Medtronic were worth $1,078,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of MDT. Brighton Jones LLC boosted its holdings in shares of Medtronic by 1,368.0% in the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after buying an additional 37,265 shares during the period. GAMMA Investing LLC boosted its stake in Medtronic by 41.1% during the 1st quarter. GAMMA Investing LLC now owns 15,882 shares of the medical technology company’s stock valued at $1,427,000 after purchasing an additional 4,626 shares during the period. Cambridge Investment Research Advisors Inc. boosted its stake in Medtronic by 16.3% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 176,438 shares of the medical technology company’s stock valued at $15,855,000 after purchasing an additional 24,777 shares during the period. JFS Wealth Advisors LLC boosted its stake in Medtronic by 58.7% during the 1st quarter. JFS Wealth Advisors LLC now owns 3,948 shares of the medical technology company’s stock valued at $355,000 after purchasing an additional 1,460 shares during the period. Finally, Asset Management One Co. Ltd. boosted its stake in Medtronic by 5.1% during the 1st quarter. Asset Management One Co. Ltd. now owns 565,134 shares of the medical technology company’s stock valued at $50,783,000 after purchasing an additional 27,232 shares during the period. 82.06% of the stock is owned by institutional investors and hedge funds.

Medtronic Stock Performance

Shares of MDT opened at $95.84 on Wednesday. The company’s 50 day moving average price is $94.20 and its 200 day moving average price is $89.13. Medtronic PLC has a 52 week low of $79.29 and a 52 week high of $99.37. The company has a market capitalization of $122.93 billion, a PE ratio of 26.40, a PEG ratio of 2.53 and a beta of 0.78. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.50 and a current ratio of 2.01.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 EPS for the quarter, topping the consensus estimate of $1.23 by $0.03. The company had revenue of $8.58 billion during the quarter, compared to the consensus estimate of $8.37 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The company’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.23 earnings per share. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. Research analysts expect that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 17th. Shareholders of record on Friday, September 26th were given a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend was Friday, September 26th. Medtronic’s payout ratio is currently 78.24%.

Insider Activity at Medtronic

In related news, EVP Harry Skip Kiil sold 8,605 shares of the company’s stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total transaction of $788,045.90. Following the completion of the sale, the executive vice president directly owned 35,615 shares of the company’s stock, valued at approximately $3,261,621.70. This represents a 19.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director William R. Jellison acquired 2,500 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The shares were purchased at an average cost of $92.37 per share, with a total value of $230,925.00. Following the completion of the acquisition, the director owned 5,000 shares in the company, valued at $461,850. This trade represents a 100.00% increase in their position. The disclosure for this purchase can be found here. Insiders own 0.26% of the company’s stock.

Analysts Set New Price Targets

MDT has been the subject of a number of analyst reports. Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a research note on Wednesday, October 8th. William Blair raised shares of Medtronic to a “hold” rating in a research note on Friday, July 11th. Royal Bank Of Canada reissued an “outperform” rating and set a $111.00 target price on shares of Medtronic in a research note on Friday, October 10th. Wells Fargo & Company boosted their target price on shares of Medtronic from $98.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, August 20th. Finally, BTIG Research reissued a “neutral” rating on shares of Medtronic in a research note on Friday, July 11th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $102.82.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.